



#6
1614
7-6-2

THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicants: Xue-Feng Pei, Baoqing Li and Maria-Luisa Maccacchini

JUN 26 2002

Serial No.: 09/882,843

Art Unit: 1614

TECH CENTER 1600/2900

Filed: June 15, 2001

Examiner: Not Yet Assigned

For: *5H-2,3-BENZODIAZEPINE ANTAGONISTS OF EXCITATORY AMINO ACID RECEPTORS*

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including three (3) pages of Form PTO-1449 and a copy of each document cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
5,716,956	02-10-1998	Pelletier	514/248

Publications

"Advanced Organic Chemistry," 4th Edition, 1992, Wiley-Interscience Publication, New York.

CHEN, "Evaluation of five methods for testing anticonvulsant activities," *Proc. Soc. Exp. Biol. Med.* 87:334 (1954).

DONEVAN & ROGAWSKI, "GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses," *Neuron* 10:51-59 (1993).

HUSSY, et al., "Functional properties of a cloned 5-hydroxytryptamine Ionotropic receptor subunit: Comparison with native mouse receptors," *J. Physiol. (London)* 481(2):311-323 (1994).

LE PEILLET, et al., "The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat," *Brain Res.* 571:115-120 (1992).

LIPTON & ROSENBERG, "Excitatory amino acids as a final common pathway for neurologic disorders," *New England Journal of Medicine* 330:613-622 (1994).

MCBURNEY, "Therapeutic potential of NMDA antagoniate in neurodegenerative diseases," *Neurobiology of Aging* 15:271-273 (1994).

MELDRUM, "Excitatory amino acids in epilepsy and potential novel therapies," *Epilepsy Research* 12:189-196 (1992).


Remington's Pharmaceutical Sciences 17th Edition, p. 1418 (1985).

SMITH & MELDRUM, " Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat," *Stroke* 23:861 (1992).

TARNAWA, et al., "Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GKYI 52466," *Eur. J. Pharmacol* 167:193-199 (1989).

YAMAGUCHI, et al., "Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models," *Epilepsy Research* 15:179-184 (1993).

U.S.S.N.: 09/882,843
Filed: June 15, 2001
INFORMATION DISCLOSURE STATEMENT



Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,


A handwritten signature in black ink, appearing to read "Patrea L. Pabst". The signature is written over a horizontal line.

Patrea L. Pabst
Reg. No. 31,284

Dated: June 14, 2002

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com


U.S.S.N.: 09/882,843
Filed: June 15, 2001
INFORMATION DISCLOSURE STATEMENT



Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: June 14, 2002


Aisha Wyatt

ATL1 #524513 v1